

Global Gene Therapy Market Expected to Reach \$4,300 Million by 2021: Polaris Market Research

BROOKLYN, NY, UNITED STATES, January 31, 2018 /EINPresswire.com/ -- The Global [Gene Therapy market size is expected to reach USD 4,300 million](#) market by 2021 as reported by Polaris Market Research.



The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies as a therapy option for the critical and deadly indications. The positive attitude of regulatory bodies has also created a favorable environment for the research and development in these therapies.

“

The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies.”

Polaris Market Research

As of January 2018, there are 3000+ Reported Clinical Trials for Gene therapies, out of which 500+ trials are currently ongoing. The increase in the government funds for the research and development also paving the way for the secure future of gene therapies in coming time.

Polaris Market Research expects that with the expected launch of the potential gene therapies, the market is expected to rise at a higher pace. The United States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the approval of KYMRIAH (Novartis), YESCARTA (Kite Pharmaceuticals) and

LUXTURNA (Spark Therapeutics) and associated premium pricing.

Currently the [Gene Therapy market](#) is highly fragmented but with the current initiatives taken by the government and fastened approval process in developed countries, the market is soon going to be regulated.

The only restraint to the Gene Therapy market is premium pricing of the therapies. Polaris Market Research believes that the affordability of gene therapy is one of the primary concern in the mature markets. GlaxoSmithKline recently in October 2017 launched the gene therapy, STRIMVELIS for the ultra-rare disorder i.e. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (AD-SCID) This drug comes with the price tag of \$665,000 which makes it THE expensive drug in the entire [gene therapy segment](#). The drug also comes with money back guarantee as reported by the company itself.

Polaris Market Research has provided the forecasts of the Global Gene Therapy Market from 2016-2021.

The major segments which has been investigated in the global market from 2016-2021 are:

1. Market Analysis by Marketed Gene Therapies
2. Market Analysis by Companies
3. Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2021 are:

1. Rexin-G (Epeius Biotechnologies Corporation)
2. Gendicine (SiBiono GeneTech Co., Ltd)
3. Neovasculgen [Human Stem Cells Institute (HSCI)]
4. Glybera (UniQure Biopharma B.V.)
5. KYMRIAH (Novartis)
6. YESCARTA (Kite Pharmaceuticals)
7. LUXTURNA (Spark Therapeutics)
8. STRIMVELIS (GlaxoSmithKline)

The Major Indications in Gene Therapy are:

1. Cancer
2. Neurodegenerative Disorders
3. Lysosomal Storage Disorders (LSDs)
4. Ocular Diseases
5. Muscle Disorders
6. Anemia
7. Hemophilia
8. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

Leading Companies investigated in the Report are

1. Novartis Pharmaceuticals Corporation
2. Kite Pharma, Incorporated
3. Spark Therapeutics, Inc
4. GlaxoSmithKline
5. Adaptimmune
6. Bluebird bio
7. Celgene
8. Shanghai Sunway Biotech
9. Shenzhen SiBiono GeneTech
10. SynerGene Therapeutics
11. Others

Browse other reports by Polaris Market Research:

<https://www.polarismarketresearch.com/industry/Healthcare/>

Neel

Polaris Market Research & Consulting

+16465689980

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.